6533b861fe1ef96bd12c59b3
RESEARCH PRODUCT
CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors
Maryam ZahedMohammad-ali RanjbarNegar NikookarZahra Ranjbarsubject
0301 basic medicinePathologymedicine.medical_specialtyOral Medicine and PathologySalivary glandbusiness.industryResearchCancer:CIENCIAS MÉDICAS [UNESCO]Adenoidmedicine.disease03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureSalivary Gland Tissue030220 oncology & carcinogenesisNucleotidaseUNESCO::CIENCIAS MÉDICASmedicineBiomarker (medicine)ImmunohistochemistrybusinessGeneral Dentistrydescription
Background Ecto-5’-nucleotidase (CD73) plays an important role in the development of several types of cancer; however, its prognostic significance in salivary gland tumors remains unknown. The current study was conducted to investigate the expression of CD73 in such tumors. Material and Methods In this retrospective study, immunohistochemical expression of CD73 was evaluated in 25 pleomorphic adenomas, 20 mucoepidermoid carcinomas and 20 adenoid cystic carcinomas using the Envision technique. Labeling indices of CD73 expression were calculated and compared between lesions. Results Immunohistochemical analysis demonstrated that the CD73 expression was significantly higher in salivary gland tumors than in normal salivary gland tissue (p0.05). Conclusions The findings suggest that CD73 can be an independent and useful biomarker for predicting the clinical behavior of salivary gland tumors. Key words:Ecto-5’-nucleotidase, immunohistochemistry, salivary gland tumors.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2019-01-01 |